Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 18/20 | 0.52 |
| ▸ | HCRTR2 | O43614 | 17/20 | 0.52 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13628469 | 0.91 | HCRTR1 (0.49) | HCRTR1HCRTR2GRM2GRIN2BCYP3A4 | |
| SCHEMBL2028806 | 0.90 | HCRTR1 (0.53) | HCRTR1HCRTR2GRM2CYP3A4 | |
| SCHEMBL1003589 | 0.90 | HCRTR1 (0.53) | HCRTR1HCRTR2GRM2GRIN2BCYP3A4 | |
| SCHEMBL2022984 | 0.88 | GRM2 (0.47) | HCRTR1HCRTR2GRM2CYP3A4 | |
| SCHEMBL12581836 | 0.86 | HCRTR1 (0.46) | HCRTR1HCRTR2GRM2GRIN2B | |
| SCHEMBL12581822 | 0.86 | GRM2 (0.51) | HCRTR1HCRTR2GRM2GRIN2B | |
| SCHEMBL12413544 | 0.86 | GRM2 (0.49) | HCRTR1HCRTR2GRM2GRIN2B | |
| SCHEMBL2025638 | 0.85 | HCRTR1 (0.45) | HCRTR1HCRTR2GRM2GRIN2BCYP3A4 | |
| SCHEMBL12413548 | 0.84 | MEN1 (0.45) | CYP3A4 | |
| SCHEMBL2022457 | 0.84 | GRM2 (0.48) | HCRTR1HCRTR2GRM2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | VAN WAGENEN BRADFORD | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | HCRTR1 246/4885HCRTR2 327/4885GRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.